Land: Malta
Språk: engelsk
Kilde: Medicines Authority
CEFPODOXIME
Sanofi Malta Limited
J01DD13
CEFPODOXIME
FILM-COATED TABLET
CEFPODOXIME 100 mg
POM
ANTIBACTERIALS FOR SYSTEMIC USE
Authorised
2005-10-12
20/11/2008 16:33 - VISTAlink folder 216373 - Page 1/3 _c_ _ré_ _é_ _le_ _p_ _a_ _r_ _m_ _o_ _d_ _if_ _ié_ _le_ _p_ _a_ _r_ _La_ _b_ _o_ _ra_ _to_ _ire_ _s_ _P_ _a_ _y_ _s_ 2 6 /0 1 /2 0 0 7 JY P RI G E N T 1 9 /0 8 /2 0 0 8 JY P RI G E N T S A N O FI -A V E N TI S A N G LE TE RR E _C_ _o_ _u_ _le_ _u_ _r_ _N_ _b_ _re_ _/R_ _é_ _f._ 1 B LE U R E FL E X B LU E _V_ _e_ _rs_ _io_ _n_ _N_ _°_ 8 _T_ _y_ _p_ _e_ _A_ _rt_ _ic_ _le_ N O TI C E D O U B LE O RE LO X R 7 5 2 3 2 0 1 0 0 M G C P RS _N_ _o_ _m_ _d_ _u_ _p_ _ro_ _d_ _u_ _it_ _R_ _é_ _fé_ _re_ _n_ _c_ _e_ _a_ _rt_ _ic_ _le_ _D_ _o_ _sa_ _g_ _e_ _Q_ _u_ _a_ _n_ _ti_ _té_ _N_ _°_ _ve_ _rs_ _io_ _n_ _L_ _o_ _g_ _o_ _/N_ _a_ _m_ _e_ _N_ _°_ _ve_ _rs_ _io_ _n_ _C_ _o_ _u_ _n_ _tr_ _y_ _E_ _x_ _._ _N_ _°_ _p_ _la_ _n_ _D_ _im_ _e_ _n_ _si_ _o_ _n_ _n_ _e_ _l_ _N_ _°_ _p_ _la_ _n_ _p_ _o_ _sit_ _io_ _n_ _n_ _e_ _m_ _e_ _n_ _t_ _D_ _im_ _e_ _n_ _si_ _o_ _n_ _s_ _T_ _a_ _il_ _le_ _m_ _in_ _i_ _c_ _a_ _ra_ _c_ _tè_ _re_ _s_ N .A . N .A . 1 -6 0 6 0 6 2 B 6 0 6 0 6 2 -1 B 1 5 0 X 2 1 0 M M 9 ,5 P TS _N_ _u_ _m_ _é_ _ro_ _d_ _e_ _P_ _a_ _g_ _e_ _s_ 1 - 3 _C_ _o_ _d_ _e_ _sé_ _c_ _u_ _ri_ _té_ R 7 5 2 3 2 0 C O M P IÈ G N E C O M P IÈ G N E READ ALL OF THIS LEAFLET CAREFULLY BEFORE TAKING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or your pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or your pharmacist. IN THIS LEAFLET: 1. What Orelox Tablets are and what they are used for 2. Before you take Orelox Tablets 3. How to take Orelox Tablets 4. Possible side effects 5. How to store Orelox Tablets 6. Further information Orelox Tablets contains a medicine c read_full_document
Page 1 of 9 SUMMARY OF PRODUCT CHARACTERISTICS __________________________________________________________________ 1. NAME OF THE MEDICINAL PRODUCT Orelox tablets 100 mg 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Orelox tablet contains 130.45 mg of cefpodoxime proxetil (equivalent to 100 mg cefpodoxime). 3. PHARMACEUTICAL FORM Film-coated tablet for oral use 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Orelox is a bactericidal cephalosporin antibiotic active against a wide range of Gram- negative and Gram-positive organisms. It is indicated for the treatment of the following infections either before the infecting organism has been identified or when caused by bacteria of established sensitivity. Upper respiratory tract infections caused by organisms sensitive to cefpodoxime, including sinusitis. In tonsillitis and pharyngitis, Orelox should be reserved for recurrent or chronic infections, or for infections where the causative organism is known or suspected to be resistant to commonly used antibiotics. Lower respiratory tract infections caused by organisms sensitive to cefpodoxime, including acute bronchitis, relapses or exacerbations of chronic bronchitis and bacterial pneumonia. Upper and lower urinary tract infections caused by organisms sensitive to cefpodoxime including cystitis and acute pyelonephritis. Skin and soft tissue infections caused by organisms sensitive to cefpodoxime such as abscesses, cellulitis, infected wounds, furuncles, folliculitis, paronychia, carbuncles and ulcers. Page 2 of 9 Gonorrhoea – uncomplicated gonococcal urethritis. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION _Route of administration_: Oral. _ADULTS_: _ADULTS WITH NORMAL RENAL FUNCTION_: _Upper respiratory tract infections_: For upper respiratory tract infec read_full_document